Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder - Wikidata - wikimedia - TriplyDB

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

http://www.wikidata.org/entity/Q27497430

about

Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom A Systematic Review of the Literature on the Development of Condition-Specific Preference-Based Measures of Health.Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.The impact of age, gender and severity of overactive bladder wet on quality of life, productivity, treatment patterns and satisfaction

P2860

Q33696642-503756E0-2977-4200-B4C3-424EE3273952 Q34990256-F8EEA841-56C4-4672-94A9-602F946183EC Q35906213-8F649D5C-11F0-4E6E-8BB4-A36A59538827 Q38711099-85E4927A-E93B-477D-A516-A8EB74670A80 Q39146493-3B5ABE63-A906-44A5-A517-0EA8C8E91651 Q39667385-F9809D14-8AD2-44AA-AE26-9A1C26CB9017 Q50100268-7FE894C0-324D-4414-8FF0-B97E87BCD7E4 Q57824526-0FE830E1-2EB3-4BCE-9A8C-677C3DAF1EF3

P2860

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

http://www.wikidata.org/entity/Q27497430

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@ast

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@en

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@nl

type

label

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@ast

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@en

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@nl

prefLabel

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@ast

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@en

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@nl

P1433

Q27497430-45DABB16-7124-4C67-A892-4969B4B3D8A7

P1476

Q27497430-72E1CEEA-B870-4796-8FE3-0E39F439C309

P2093

Q27497430-042F047F-5ACC-4F7B-8B3D-658C8490220E

Q27497430-09D028C0-E33C-4C6A-A2F6-3C176FDD720A

Q27497430-365A5C78-B0A3-462F-97F0-9F99D5EA1339

Q27497430-7A5B3538-49F3-4F52-9C7A-86435FA169EE

Q27497430-7E3E93D6-2360-4C7D-A0D9-9CD36D967C36

Q27497430-E513358E-7DD9-4414-9428-F213CB16AB17

P2860

Q27497430-044AF070-CAF3-4C50-B50C-4F19FBF496F6

Q27497430-4AC53229-30CE-4704-B77C-53ACFC83DFEB

Q27497430-5936FC72-221F-46F3-9E11-FC3470433663

Q27497430-64C344CB-21CE-44C3-9034-BD060BA41E31

Q27497430-7AD0B8FF-82E8-492B-86AE-F0CD5184316C

Q27497430-84228F77-708A-42A6-BC5E-84E66A6636F1

Q27497430-8BAAD995-18D2-425D-9B1F-C22DB840C72B

Q27497430-8E7DE172-1B2A-4F35-9755-4BF00CA1785C

Q27497430-93536AA0-72BE-48F3-988A-DF59D92B3B2E

Q27497430-99EE359D-B1CF-42DB-A2A8-54022C9E2C3C

P2888

Q27497430-116ED504-96E1-499B-8B04-A4A091AAED24

P304

Q27497430-B915219B-829B-4ACF-BBDE-30ED21F80017

P31

Q27497430-8CEA44AD-DC56-4E1C-91EF-5A3848457603

P356

Q27497430-E80FC6BA-E143-436C-BBD3-3EFC6A99DCB3

P433

Q27497430-EC1E8852-1B74-4FFE-B2A6-2CCA6EBB6550

P478

Q27497430-565AFC64-4892-4E75-8DEE-86E2EE3E53F4

P577

Q27497430-2458D32E-A1D3-4042-B394-E707FC25E92A

P5875

Q27497430-329A62F8-C1D7-4C12-81EC-51641B6784D3

P6179

Q27497430-27590EFC-EC42-4D2D-96CB-B7A055E5D9E3

P698

Q27497430-D64FBE47-E121-4DFC-9EEE-0FB84CB587B6

P932

Q27497430-76C4577A-3A35-48E1-9F70-38DDB43E2D0A

P356

1477-7525-11-200

P1433

Health and Quality of Life Outcomes

P1476

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

@en

P2093

Isaac Odeyemi

http://www.w3.org/2001/XMLSchema#string

Jameel Nazir

http://www.w3.org/2001/XMLSchema#string

Katia Desroziers

http://www.w3.org/2001/XMLSchema#string

Khaled Maman

http://www.w3.org/2001/XMLSchema#string

Samuel Aballéa

http://www.w3.org/2001/XMLSchema#string

Zalmai Hakimi

http://www.w3.org/2001/XMLSchema#string

P2860

Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses

Comorbidities associated with overactive bladder.

Assessing responsiveness of generic and specific health related quality of life measures in heart failure

US norms for six generic health-related quality-of-life indexes from the National Health Measurement study.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Estimating a preference-based single index from the Overactive Bladder Questionnaire.

The time trade-off: a note on the effect of lifetime reallocation of consumption and discounting.

Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

P2888

1477-7525-11-200

P304

200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1477-7525-11-200

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258641180

http://www.w3.org/2001/XMLSchema#string

P6179

1039839040

http://www.w3.org/2001/XMLSchema#string

P698

24246044

http://www.w3.org/2001/XMLSchema#string

P932

3842710

http://www.w3.org/2001/XMLSchema#string